Teva's Copaxone case heard again by US Supreme Court
The patent battle over Israel-based Teva Pharmaceutical Industries’ (NYSE: TEVA) multiple sclerosis drug Copaxone (glatiramer acetate) was heard by the US Supreme Court yesterday.
Teva has filed a suit against generic drug manufacturers in their bid to launch a generic version of Copaxone when the patient expires in September 2015. The case against US generics maker Mylan (Nasdaq: MYL) was heard by the US District Court in May but dismissed.
In August Teva said it intends to file a law suit for patent infringement against Indian drugmaker Dr Reddy’s Laboratories (NYSE: RDY) within the 45 day period provided under the Hatch-Waxman Act. The filing of the law suit triggered a 30 month stay of Food and Drug Administration approval of Dr Reddy’s Abbreviated New Drug Application.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze